The observed overexpression has not been previously described for endometrial cancer but is consistent with the already published results for ovarian cancer, where it is promoted via the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/protein kinase b (AKT) pathways [56]. This evidence concerns the gene AKT1 and endometrial cancer.